Ann Young, APRN
Family · Lexington, NENPI 1831292952
Payments from drug & device makers
Across 87 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$592
- AstraZeneca$295
- Lilly USA, LLC$97
- Alkermes, Inc.$81
- Johnson & Johnson$77
- Novo Nordisk$63
- plus $368 from 17 others
What the payments were for
- Food & beverage$1,572100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $592 |
| AstraZeneca | 7 | $295 |
| Lilly USA, LLC | 7 | $97 |
| Alkermes, Inc. | 4 | $81 |
| Johnson & Johnson | 5 | $77 |
| Novo Nordisk | 4 | $63 |
| Astellas Pharma US Inc | 3 | $51 |
| Abbott | 2 | $47 |
| Novartis | 1 | $35 |
| Corcept Therapeutics | 2 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| GSK | 2 | $24 |
| Convatec Inc. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Pfizer | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Bayer | 1 | $12 |
| Genentech USA, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,572 in reported general payments places this provider in the 80th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 39 | $53,399 |
| FarxigaDapagliflozin Propanediol | 48 | $29,999 |
| RexultiBrexpiprazole | 21 | $29,370 |
| EliquisApixaban | 34 | $23,094 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $17,661 |
| XareltoRivaroxaban | 19 | $14,517 |
| EntrestoSacubitril/Valsartan | 18 | $11,173 |
| MounjaroTirzepatide | 11 | $10,385 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $8,449 |
| FetzimaLevomilnacipran Hcl | 13 | $5,703 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,518 |
| VascepaIcosapent Ethyl | 13 | $4,532 |
| DuleraMometasone/Formoterol | 11 | $3,368 |
| Aripiprazole | 13 | $2,442 |
| Potassium Chloride | 113 | $2,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $592 | $59,10152 claims |
| AstraZenecaFarxiga | $295 | $29,99948 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $14 | $29,37021 claims |
| PfizerEliquis | $13 | $23,09434 claims |
| Johnson & JohnsonXarelto | $77 | $14,51719 claims |
| NovartisEntresto | $35 | $11,17318 claims |
| Lilly USA, LLCMounjaro | $97 | $10,38511 claims |
| MerckDulera | $15 | $3,36811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 809 family providers in Nebraska.
Other family in Lexington
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
- Mary MetzLincoln$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.